



THE ESTABLISHMENT OF IMMUNO-ONCOLOGY AS THE 4TH PILLAR OF CANCER TREATMENT



Arvin Yang, M.D., Ph.D.

VICE PRESIDENT AND HEAD

HEMATOLOGY CLINICAL DEVELOPMENT AT BRISTOL-MYERS SQUIBB (BMS)

Arvin Yang is currently the Vice President, Head of Clinical Hematology at Bristol-Myers Squibb Company. Previously, he was the Development Lead for Melanoma/Genitourinary (GU) Cancers at Bristol-Myers Squibb Company. In this role, Arvin was responsible for the vision and growth strategy for Melanoma and Genitourinary (GU) cancers including Renal Cell Carcinoma, Bladder, and Prostate Cancer. He joined BMS in 2010 and with prior roles including Early Asset Oncology Development Lead, as well as the Nivolumab-Ipilimumab Life Cycle Management Medical Lead.

Arvin has spent over 17 years focused on the development of immuno-oncology agents and drug development. He received his M.D. and Ph.D. in Tumor immunology from the University of Medicine and Dentistry of New Jersey. He completed his residency in Internal Medicine Residency at Beth Israel Deaconess Medical Center/Harvard Medical School Teaching Hospital followed by a Medical Oncology Fellowship at Memorial Sloan Kettering Cancer Center.



ABSTRACT

Checkpoint inhibitors are now established as the 4th pillar of cancer therapy applicable to a broad spectrum of malignancies. An overview will be provided of the clinical challenges associated with development including assessment of clinical benefit, safety management and biomarker strategies. In addition, we'll discuss the future opportunities within immuno-oncology.